Description

Semaglutide is a GLP-1 agonist created for Type 2 Diabetes. It was approved for the indication of weight loss as Wegovy in June 2021.

ALSO KNOWN AS: Semaglutide

AVOID WHEN: History of Thyroid C-cell tumors; Pregnant; Breastfeeding; Trying to conceive; History of anorexia/bulimia

SIDE EFFECTS: Nausea (44%); Vomiting (25%); Diarrhea/GI distress (30%)

How it Works

GLP-1 works to increase insulin levels by activating cells in the pancreas. It also triggers hormone release to delay the emptying of the stomach, sometimes causing nausea.

Expected Results

When used alongside robust lifestyle management (200 min exercise/week, nutri-system diet, bimonthly nutritionist visits) patients observed 10-14% weight loss, maintained over 2 years (STEP3 Trial, Novo Nordisk).

Description

Tirzepatide is the newest form of weight loss medication. It was recently approved for Type 2 diabetes, and works through both the GLP-1 receptor and GIP receptors. Both of these work to slow stomach emptying and decrease appetite.

ALSO KNOWN AS: Mounjaro & Zepbound

AVOID WHEN: Chronic malabsorption; Pregnancy; Cholestasis/History of Gallbladder disease; Pancreatitis; Family history of Thyroid Cancer; Thyroid disorders

SIDE EFFECTS: Nausea (44%); Vomiting (25%); Diarrhea/GI distress (30%)

How it Works

Both GLP-1 and GIP receptors work to decrease the rate your stomach empties– keeping you full for longer! They also work to decrease your appetite and cravings.

Expected Results

The SURMOUNT-1 trial showed expected weight loss of 22.5%. Additional trials have shown this medication is twice as effective as Semaglutide 1.0mg.